Abstract:
:Many patients chronically infected by hepatitis C virus (HCV) experience symptoms like fatigue, dyspnea and reduced physical activity. However, in many patients, these symptoms are not proportional to the liver involvement and could resemble symptoms of chronic heart failure. To our knowledge, no study evaluated serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) in a large series of patients with HCV chronic infection (HCV+). Serum NT-proBNP was assayed in 50 patients HCV+ and in 50 sex- and age-matched controls. HCV+ patients showed significantly higher mean NT-proBNP level than controls (P = 0.001). By defining high NT-proBNP level as a value higher than 125 pg/mL (the single cut-off point for patient under 75 years of age), 34% HCV+ and 6% controls had high NT-proBNP (Fisher exact test; P < 0.001). With a cut-off point of 300 pg/mL (used to rule out chronic heart failure in patients under 75 years of age) 10% HCV+ and 0 controls had high NT-proBNP (Fisher exact test; P = 0.056). With a cut-off point of 900 pg/mL (used for ruling in chronic heart failure in patients with age 50-75) 8% HCV+ patients and 0 controls had high NT-proBNP (Fisher exact test; P = 0.12). The study demonstrates high levels of circulating NT-proBNP in HCV+ patients compared to healthy controls. The increase of NT-proBNP may indicate the presence of a sub-clinical cardiac dysfunction. Further prospective studies quantifying these symptoms in correlation with echocardiography are needed to confirm this association.
journal_name
J Viral Hepatjournal_title
Journal of viral hepatitisauthors
Antonelli A,Ferri C,Ferrari SM,Colaci M,Sebastiani M,Zignego AL,Ghiri E,Goglia F,Fallahi Pdoi
10.1111/j.1365-2893.2009.01237.xsubject
Has Abstractpub_date
2010-12-01 00:00:00pages
851-3issue
12eissn
1352-0504issn
1365-2893pii
JVH1237journal_volume
17pub_type
杂志文章abstract::Serological and biochemical studies indicate that acute HBV infection is resolved in the context of an efficient cell-mediated immune (CMI) response, whereas, chronic infection is characterized by weak to undetectable CMI responses and relatively efficient humoral immunity. Because humoral immunity and CMI are regulat...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.1997.tb00180.x
更新日期:1997-01-01 00:00:00
abstract::Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment fa...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究
doi:10.1111/jvh.12427
更新日期:2015-12-01 00:00:00
abstract::The triglycerides × glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2011.01439.x
更新日期:2011-07-01 00:00:00
abstract::In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non-Black patients but also a higher frequency of HCV genotype 1 (GT-1) infection. The aim of this community-based study was to determine whether Black p...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究
doi:10.1111/j.1365-2893.2005.00682.x
更新日期:2006-04-01 00:00:00
abstract::IL28B and inosine triphosphatase (ITPA) polymorphisms are able to predict treatment response and degree of ribavirin-related anaemia, respectively, in the treatment of chronic hepatitis C virus (HCV) infection. However, their roles in the treatment of chronic HCV genotype 6 remain undetermined. Sixty patients who were...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12047
更新日期:2013-07-01 00:00:00
abstract::The treatment option in chronic hepatitis B (CHB) patients with persistent low-level viremia despite entecavir or tenofovir monotherapy is unclear. This study investigated the development of hepatocellular carcinoma (HCC) or cirrhosis in hepatitis B e antigen (HBeAg)-positive high viral load CHB patients, according to...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12838
更新日期:2018-05-01 00:00:00
abstract::Response to interferon-alpha (IFN-alpha) treatment in hepatitis C is poorer when cirrhosis is present. In the third Australian multicentre hepatitis C trial, Aushep-3, we examined the efficacy and tolerability of an intensive 24-week course of interferon-alpha 2a in Child-Pugh grade A patients with chronic hepatitis C...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1046/j.1365-2893.1997.00062.x
更新日期:1997-09-01 00:00:00
abstract::Chronic hepatitis B (CHB) is characterized by an impaired immune response to hepatitis B virus. Among the nucleos(t)ides used in CHB treatment, telbivudine is associated with the highest rates of hepatitis B e antigen (HBeAg) seroconversion rates, which are similar to those observed with pegylated interferon (PegIFN)....
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/jvh.12059
更新日期:2013-04-01 00:00:00
abstract::The focus of this study was to evaluate the safety and efficacy of sequential peginterferon α-2a (Pegasys) therapy for chronic hepatitis B with acute exacerbation [ALT > 10 × upper limit of normal (ULN), bilirubin <2.0 mg/dL]. Four groups of patients categorized by HBeAg status and treatment regimens were studied sinc...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章
doi:10.1111/j.1365-2893.2011.01469.x
更新日期:2012-03-01 00:00:00
abstract::Quantitative serology for hepatitis B surface antigen (HBsAg) is a new candidate marker for prediction of clinical outcome. The aim of this study was to investigate the clinical significance of quantifying HBsAg in patients with hepatitis B virus (HBV) infection. A total of 424 patients who tested positive for HBsAg a...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2011.01486.x
更新日期:2011-10-01 00:00:00
abstract::Although tattooing is recognized as a risk factor for transmission of hepatitis C, the efficiency with which transmission occurs is unknown. Sera stored from a serosurvey of tattooists undertaken in 1984 to test for human immunodeficiency virus (HIV) provided the opportunity to determine the prevalence of serological ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.1997.tb00216.x
更新日期:1997-03-01 00:00:00
abstract::The non-structural (NS)5A protein of hepatitis C virus (HCV) is cleaved, after translation, by the NS3-encoded zinc-dependent serine proteinase, from the NS4B protein upstream and the NS5B protein downstream. The released, mature NS5A protein is a 56 000 MW phosphoprotein (p56), which also exists within infected cells...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1046/j.1365-2893.1999.00185.x
更新日期:1999-09-01 00:00:00
abstract::It is unclear whether the achievement of virologic response modifies the risk of hepatocellular carcinoma (HCC) differently in chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Our aim was to compare the risk of HCC between patients with CHB and CHC who achieved virological response. We analysed data from patie...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12723
更新日期:2017-11-01 00:00:00
abstract::Hepatocellular carcinoma (HCC) is the most common complication of HCV infection leading to liver transplantation. We evaluated the impact of aetiology of liver disease on patient and graft survival following liver transplantation for HCC. From the Scientific Registry of Transplant Recipients (2002-2011), all adults wh...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12449
更新日期:2016-01-01 00:00:00
abstract::The ECHO model was developed to expand access to medical care for populations with HCV infection in underserved areas. We aimed to compare HCV treatment outcomes in community-based clinics with the Austral University Hospital (AUH) and to assess improvement in physician knowledge and skills. In October 2015, we establ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13172
更新日期:2019-11-01 00:00:00
abstract::To evaluate, among 70 hepatitis C virus (HCV)-monoinfected and 36 human immunodeficiency virus (HIV)-coinfected naïve patients with genotypes 1/4 receiving weight-adjusted pegylated interferon-alpha-2b/ribavirin, viral kinetics and the feasibility to predict treatment failure measuring early HCV-RNA decreases. HCV-RNA...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2005.00710.x
更新日期:2006-07-01 00:00:00
abstract::Hepatitis B virus (HBV) infection induces a wide range of chronic liver injury. The mechanism by which HBV evades the immune surveillance system remains obscure. Plasmacytoid dendritic cells (pDCs) seem to be the major endogenous interferon (IFN)-alpha producers and represent one of the most important cell types in th...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2006.00819.x
更新日期:2007-04-01 00:00:00
abstract::Socio-demographic and behavioural characteristics are associated with delayed diagnosis and disease progression in HCV-infected persons. However, many analyses focused on single variables rather than groups defined by several variables. We used latent class analysis to study all 4488 persons enrolled in the Swiss Hepa...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12535
更新日期:2016-09-01 00:00:00
abstract::Hepatitis E virus (HEV) represents one of the foremost causes of acute hepatitis globally. Although there is no proven medication for hepatitis E, pegylated interferon-α (IFN-α) has been used as off-label drug for treating HEV. However, the efficacy and molecular mechanisms of how IFN signalling interacts with HEV rem...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12491
更新日期:2016-04-01 00:00:00
abstract::Summary. Directly acting antiviral (DAA) agents are currently revolutionizing the treatment of chronic hepatitis C infection. The first generation of these agents have significant limitations including cost issues that are of particular concern in the developing world and a lack of efficacy in genotype 3 patients. Bo...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2012.01613.x
更新日期:2013-05-01 00:00:00
abstract::Oral therapy for chronic hepatitis B remains suboptimal. Mathematical modelling of viral decay kinetics to rapidly assess potential antiviral regimens has proved valuable for human immunodeficiency virus and cytomegalovirus. We defined the kinetics of viral replication in 10 chronic hepatitis B patients randomized to ...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1111/j.1365-2893.2004.00523.x
更新日期:2004-09-01 00:00:00
abstract::Over 70 million individuals are infected with hepatitis C virus (HCV) worldwide. Yet most prevalence data are in the adult population, with little focus on paediatrics, partially due to the scarcity of public data. The objective of this paper is to examine HCV prevalence in children by estimating prevalence rates amon...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13377
更新日期:2020-12-01 00:00:00
abstract::The objectives of this study were to investigate the prevalence of infections with hepatotrophic viruses in an anti-human immunodeficiency virus (HIV)-positive population from Buenos Aires and to compare it among the main risk groups for HIV infection. Four hundred and eighty-four consecutive patients attending the HI...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究
doi:10.1046/j.1365-2893.1999.t01-1-6120135.x
更新日期:1999-01-01 00:00:00
abstract::Primary or secondary failure of adefovir dipivoxil (ADV) therapy of chronic hepatitis B is not infrequent. The reasons for suboptimal responses are not well defined. In HIV and hepatitis C virus infection, failure of antiviral drug therapy has been linked with low blood drug levels. We have studied 20 well-defined pat...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2010.01404.x
更新日期:2011-07-01 00:00:00
abstract::Clinical and experimental studies have demonstrated that connective-tissue growth factor (CTGF) expression is increased in fibrotic human liver and experimental animal models of liver fibrogenesis. CTGF has been linked to transforming growth factor-beta (TGF-beta) pathways in fibroproliferative diseases and specific p...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2009.01110.x
更新日期:2009-09-01 00:00:00
abstract::A large number of studies have reported on spontaneous viral clearance rates in acute hepatitis C infection, however most have been small, and reported rates have varied quite widely. To improve the precision of the estimated rate of spontaneous viral clearance, a systematic review was conducted of longitudinal studie...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/j.1365-2893.2005.00651.x
更新日期:2006-01-01 00:00:00
abstract::Reports have described a decrease in glomerular filtration rate (eGFR) associated with tenofovir disoproxil fumarate (TDF) use in HIV positive individuals. However, no study has examined renal function over a prolonged period in HIV/hepatitis B virus (HBV) co-infected patients. We assessed the long-term durability and...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2009.01084.x
更新日期:2009-07-01 00:00:00
abstract::Chronic hepatitis C virus (HCV) infection eventually leads to cirrhosis in 20-30% of patients and to hepatocellular carcinoma (HCC) in 1-5% of patients. Rates of sustained virological response with standard interferon-alpha (IFN-alpha) are low in patients without cirrhosis (generally < 20%) and are even lower in those...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1046/j.1365-2893.2000.00229.x
更新日期:2000-09-01 00:00:00
abstract::Italy is one of the countries on track with the WHO's agenda to eliminate hepatitis C virus (HCV) by 2030. Healthcare facilities play a crucial role in seeking patients who are infected but have not yet been treated. We assessed the effectiveness of a recall strategy, named 'Telepass' project, for patients exposed to ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13465
更新日期:2021-01-09 00:00:00
abstract::The efficacy of lamivudine re-treatment in chronic hepatitis B (CHB) patients who relapse after HBeAg seroconversion with lamivudine has not been investigated. The aim of this study was to evaluate the efficacy of lamivudine re-treatment in relapsed patients. Among 192 patients who had achieved HBeAg seroconversion wi...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章
doi:10.1111/j.1365-2893.2005.00606.x
更新日期:2005-07-01 00:00:00